Search Results 931-940 of 16974 for monoclonal antibody

  1. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

    Monoclonal antibodies (anti-CD38 and anti-SLAMF7 antibody) within 4 weeks prior to leukapheresis;; Any other systemic therapy approved for the treatment of ...

  2. Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients - Mayo Clinic

    Monoclonal antibodies: Subjects who have received any monoclonal antibody within 5 half-lives of Visit 1. Investigational medications: Subjects who have ...

  3. Interpreting the News: COVID-19 Experimental Vaccines

    What is the significance of the BNT162b2 vaccine reportedly causing both antibodies and T cells to be made by the host? The immune system has two arms: humoral ...

  4. Services - Immune Monitoring Core - Mayo Clinic Research

    Services · Mass cytometry- CyTOF using the Helios instrument. · Custom heavy metal conjugation of antibodies through collaboration with the Antibody Hybridoma ...

  5. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

    Serum monoclonal paraprotein (M-protein) level ≥ 1.0 gram per deciliter ... Monoclonal antibody treatment within 21 days. Cytotoxic therapy within 14 ...

  6. Ulcerative colitis - Diagnosis and treatment - Mayo Clinic

    Kaplan GG. Monoclonal antibody risankizumab for ulcerative colitis. JAMA. 2024; doi:10.1001/jama.2024.8819. Related.

  7. Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy - Mayo Clinic

    Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies; Pregnant or ...

  8. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Monoclonal plasma cells in the bone marrow ≥ 10% at ... Subject has known allergies, hypersensitivity, or intolerance to VELCADE, monoclonal antibodies ...

  9. Study in Pediatrics with HypEREosinophilic Syndrome - Mayo Clinic

    Participants who have received any other monoclonal antibodies ... Participants with any history of hypersensitivity to any monoclonal antibody (including ...

  10. Palivizumab (intramuscular route) - Side effects & uses - Mayo Clinic

    It belongs to a group of medicines known as immunizing agents. This medicine works by giving your body antibodies to protect it against RSV infection. RSV ...